These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 29426698)

  • 1. External beam radiotherapy with or without androgen deprivation therapy in elderly patients with high metastatic risk prostate cancer.
    Dell'Oglio P; Bandini M; Leyh-Bannurah SR; Tian Z; Trudeau V; Larcher A; Fossati N; Moschini M; Gandaglia G; Capitanio U; Briganti A; Graefen M; Montorsi F; Saad F; Karakiewicz PI
    Urol Oncol; 2018 May; 36(5):239.e9-239.e15. PubMed ID: 29426698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of the Rate of Adherence to International Guidelines for Androgen Deprivation Therapy with External-beam Radiation Therapy: A Population-based Study.
    Dell'Oglio P; Abou-Haidar H; Leyh-Bannurah SR; Tian Z; Larcher A; Gandaglia G; Fossati N; Shariat SF; Capitanio U; Briganti A; Montorsi F; Graefen M; Saad F; Karakiewicz PI
    Eur Urol; 2016 Sep; 70(3):429-35. PubMed ID: 26951945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The need for androgen deprivation therapy in patients with intermediate-risk prostate cancer treated with dose-escalated external beam radiation therapy.
    Dong Y; Ruth KJ; Churilla TM; Viterbo R; Sobczak ML; Smaldone MC; Chen DY; Uzzo RG; Hallman MH; Horwitz EM
    Can J Urol; 2017 Feb; 24(1):8656-8662. PubMed ID: 28263132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medical androgen deprivation therapy and increased non-cancer mortality in non-metastatic prostate cancer patients aged ≥66 years.
    Abdollah F; Sammon JD; Reznor G; Sood A; Schmid M; Klett DE; Sun M; Aizer AA; Choueiri TK; Hu JC; Kim SP; Kibel AS; Nguyen PL; Menon M; Trinh QD
    Eur J Surg Oncol; 2015 Nov; 41(11):1529-39. PubMed ID: 26210655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the effectiveness of adding androgen deprivation to modern dose-escalated radiotherapy for men with favorable intermediate-risk prostate cancer.
    Falchook AD; Basak R; Mohiuddin JJ; Chen RC
    Cancer; 2016 Aug; 122(15):2341-9. PubMed ID: 27191936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival outcomes of radiotherapy with or without androgen-deprivation therapy for patients with intermediate-risk prostate cancer using the National Cancer Data Base.
    Amini A; Rusthoven CG; Jones BL; Armstrong H; Raben D; Kavanagh BD
    Urol Oncol; 2016 Apr; 34(4):165.e1-9. PubMed ID: 26699831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival After Conservative Management Versus External Beam Radiation Therapy in Elderly Patients With Localized Prostate Cancer.
    Dell'Oglio P; Boehm K; Trudeau V; Tian Z; Larcher A; Leyh-Bannurah SR; Moschini M; Capitanio U; Shariat SF; Briganti A; Montorsi F; Saad F; Karakiewicz PI
    Int J Radiat Oncol Biol Phys; 2016 Dec; 96(5):1037-1045. PubMed ID: 27478167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Final Report of the Intergroup Randomized Study of Combined Androgen-Deprivation Therapy Plus Radiotherapy Versus Androgen-Deprivation Therapy Alone in Locally Advanced Prostate Cancer.
    Mason MD; Parulekar WR; Sydes MR; Brundage M; Kirkbride P; Gospodarowicz M; Cowan R; Kostashuk EC; Anderson J; Swanson G; Parmar MK; Hayter C; Jovic G; Hiltz A; Hetherington J; Sathya J; Barber JB; McKenzie M; El-Sharkawi S; Souhami L; Hardman PD; Chen BE; Warde P
    J Clin Oncol; 2015 Jul; 33(19):2143-50. PubMed ID: 25691677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Posttreatment Prostate-Specific Antigen 6 Months After Radiation With Androgen Deprivation Therapy Predicts for Distant Metastasis-Free Survival and Prostate Cancer-Specific Mortality.
    Naik M; Reddy CA; Stephans KL; Ciezki JP; Garcia J; Grivas P; Stephenson AJ; Klein EA; Tendulkar RD
    Int J Radiat Oncol Biol Phys; 2016 Nov; 96(3):617-23. PubMed ID: 27681757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial.
    Mottet N; Peneau M; Mazeron JJ; Molinie V; Richaud P
    Eur Urol; 2012 Aug; 62(2):213-9. PubMed ID: 22502942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival Outcomes in Octogenarian and Nonagenarian Patients Treated with First-line Androgen Deprivation Therapy for Organ-confined Prostate Cancer.
    Dell'Oglio P; Bishr M; Boehm K; Trudeau V; Larcher A; Tian Z; Sosa J; Moschini M; Saad F; Capitanio U; Briganti A; Graefen M; Montorsi F; Karakiewicz PI
    Eur Urol Focus; 2018 Dec; 4(6):834-841. PubMed ID: 28753853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Androgen deprivation therapy and the risk of death from prostate cancer among men with favorable or unfavorable intermediate-risk disease.
    Keane FK; Chen MH; Zhang D; Moran BJ; Braccioforte MH; D'Amico AV
    Cancer; 2015 Aug; 121(16):2713-9. PubMed ID: 25925789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of androgen-deprivation therapy and radiotherapy for older men with locally advanced prostate cancer.
    Bekelman JE; Mitra N; Handorf EA; Uzzo RG; Hahn SA; Polsky D; Armstrong K
    J Clin Oncol; 2015 Mar; 33(7):716-22. PubMed ID: 25559808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgen deprivation therapy during and after post-prostatectomy radiotherapy in patients with prostate cancer: a case control study.
    Kim M; Song C; Jeong IG; Choi SK; Park M; Shim M; Kim YS; You D; Hong JH; Kim CS; Ahn H
    BMC Cancer; 2018 Mar; 18(1):271. PubMed ID: 29523103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Large institutional variations in use of androgen deprivation therapy with definitive radiotherapy in a population-based cohort of men with intermediate- and high-risk prostate cancer.
    Ong WL; Foroudi F; Evans S; Millar J
    BJU Int; 2017 Nov; 120 Suppl 3():35-42. PubMed ID: 28749017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiotherapy with or without androgen deprivation therapy in intermediate risk prostate cancer?
    Amit U; Lawrence YR; Weiss I; Symon Z
    Radiat Oncol; 2019 Jun; 14(1):99. PubMed ID: 31182119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of time to testosterone rebound and comorbidity on the risk of cause-specific mortality in men with unfavorable-risk prostate cancer.
    McDuff SGR; Chen MH; Renshaw AA; Loffredo MJ; Kantoff PW; D'Amico AV
    Cancer; 2018 Apr; 124(7):1391-1399. PubMed ID: 29338073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Androgen deprivation therapy in combination with radiotherapy for high-risk clinically localized prostate cancer.
    Nishiyama T
    J Steroid Biochem Mol Biol; 2012 Apr; 129(3-5):179-90. PubMed ID: 22269996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Upfront androgen deprivation therapy with salvage radiation may improve biochemical outcomes in prostate cancer patients with post-prostatectomy rising PSA.
    Jang JW; Hwang WT; Guzzo TJ; Wein AJ; Haas NB; Both S; Vapiwala N
    Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):1493-9. PubMed ID: 22401922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is androgen deprivation therapy necessary in all intermediate-risk prostate cancer patients treated in the dose escalation era?
    Castle KO; Hoffman KE; Levy LB; Lee AK; Choi S; Nguyen QN; Frank SJ; Pugh TJ; McGuire SE; Kuban DA
    Int J Radiat Oncol Biol Phys; 2013 Mar; 85(3):693-9. PubMed ID: 22836052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.